FGF2 and acute myeloid leukemia: Alternatively, fibroblast growth factor 2 (FGF2) packaged within BM-MSC EVs protects AML leukemic cells against tyrosine kinase inhibitors (TKIs) through heightened FGF2-FGFR signaling, which participates in stromal growth and paracrine protection (55).